[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ischemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ischemia":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,44,76,119,153,175,195,212,242,263],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100579812","mhealth-cardiac-rehabilitation-for-inoca-100579812",false,"NCT06829160","mHealth-CArdiac REhabilitation for INOCA","mHealth-CArdiac REhabilitation for INOCA (INOCA-CARE)","Inclusion Criteria:\n\n* Age 18 and over\n* Diagnosis of Ischemia with Non-Obstructive Coronary Arteries (INOCA) based on evidence of ischemia and\u002For ischemic symptoms, plus non-obstructive Coronary artery disease (CAD) on computed tomography (CT) or invasive angiography\n\nExclusion Criteria:\n\n* Seattle Angina Questionnaire (SAQ) = 100\n* Non-ambulatory\n* Pregnant\n* Moderate or severe cognitive impairment\n* Unable\u002Fwilling to provide consent\n* Incarcerated\n* Unable to use mHealth\n* Severe osteoarthritis or joint replacement within 3 months\n* Parkinsons disease or other movement disorders\n* Regular use of walker\n* Life expectancy \\\u003C 12 months\n* Clinical judgement concerning other safety or non-adherence issues\n* Unable to read and communicate in English since the app content is currently only available in English.","ALL","18 Years",{"count":19,"type":20},250,"ESTIMATED","INTERVENTIONAL",[23],"NA","This is a multi-site phase II, 2:1 pragmatic randomized trial of 250 participants within the NYU Langone Health (NYULH) and Emory University Medical Center system to evaluate mobile health cardiac rehabilitation (mHealth-CR) in patients who meet clinical criteria for INOCA (ischemia and no obstructive coronary disease on imaging). Participants will be randomized to mHealth-CR or usual care. The study intervention takes place for 3 months which is the time period for most traditional CR programs.\n\nThe overall study goals are threefold: 1) to evaluate whether an mHealth-CR intervention that includes activity tracking, weekly counseling, and exercise documentation, improves health status (i.e., symptoms, function, and quality of life) in patients with INOCA at 3 months; 2) to evaluate effects of the mHealth-CR intervention vs. usual care on physical activity and exercise capacity, general health status, and depressive symptoms (secondary endpoints). We will also evaluate effects on primary and secondary outcomes at 6 months and 1 year; and 3) to characterize engagement and elucidate any factors that limit engagement.",[26],"Ischemia",[28,29,26,30],"INOCA","ANOCA","no obstructive coronary artery disease","RECRUITING","2026-04-21",{"date":34,"type":35},"2026-04-23","ACTUAL",{"date":37,"type":35},"2025-03-21",{"date":39,"type":20},"2029-05",{"name":41,"class":42},"NYU Langone Health","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100536957","smartphone-twelve-lead-ecg-utility-in-st-elevation-myocardial-infarction-ii-100536957","NCT06271577","Smartphone Twelve-Lead ECG Utility In ST-Elevation Myocardial Infarction II","Smartphone Twelve-Lead ECG Utility In ST-Elevation Myocardial Infarction II (STLEUISII)","STLEUISII","Inclusion Criteria:\n\n* Male or female \\> 18 years of age.\n* Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of any study procedures.\n* Symptoms of chest pain upon presentation at the Emergency Department of the participating institution.\n\nExclusion Criteria:\n\n* Inability or refusal of the patient and\u002For the patient's legally acceptable representative to provide written informed consent for any reason.\n* Other conditions that in the opinion of the Lead Investigator may increase risk to the subject and\u002For compromise the quality of the clinical trial.",true,{"count":54,"type":20},1000,[23],"AliveCor (www.alivecor.com) has developed several electrocardiogram (ECG) devices that interface with iOS and Android smartphones and tablets via various Kardia apps. The current Kardia family of devices can measure single lead and six limb-lead ECGs, depending on the device. KardiaMobile, KardiaMobile 6L, and KardiaMobile Card have FDA clearance for ECG rhythm recording. A modified single-lead Kardia smartphone 12-lead ECG was previously validated in the multicenter ST LEUIS study for the diagnosis of ST-Segment Elevation Myocardial Infarction (STEMI) and Non-ST-Elevation Myocardial Infarction (NSTEMI).\n\nRecently, AliveCor developed a new device: AliveCor (AC) 12-lead (12L) ECG System to record simultaneously 4 leads of ECG and then generate complete 12-lead ECGs. A previous protocol at the University of Oklahoma involved 200 subjects with early prototypes of the AC 12L device with the specific aim to validate that it accurately generated 12-lead ECGs as compared to simultaneously acquired FDA-cleared 12-lead ECGs. The prototype version of the AliveCor 12L ECG System simultaneously measured four channels of ECG (leads I, II, V2, V4), calculated the remaining limb leads as is standard for 12-lead ECGs (Leads III, aVR, aVL, aVF) and synthesized the remaining 4 precordial ECG leads (V1, V3, V5, V6). This protocol will serve to validate the production version of the system against standard 12-Lead ECGs for the diagnosis of STEMI and NSTEMI in patients admitted to the Emergency Department or directly to the Cardiac Cath Lab for the evaluation of chest pain. It is anticipated that the waveforms for each of the 12 leads from the AC 12L ECG System will be highly correlated with the corresponding leads from the comparator commercially available 12-lead ECG devices used at participating sites. The purpose of this study is to clinically validate that the four-channel AC 12L ECG device can enable the diagnosis of STEMI and NSTEMI in a non-inferior manner to existing 12-lead ECG devices.",[58,26,59,60,61,62,63,64],"Myocardial Infarction","Myocardial Ischemia","Heart Diseases","Cardiovascular Diseases","Vascular Diseases","Heart Attack","Heart Failure","2026-04-08",{"date":67,"type":35},"2026-04-09",{"date":69,"type":35},"2024-03-12",{"date":71,"type":20},"2027-03",{"name":73,"class":74},"AliveCor","INDUSTRY",4,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":84,"targetDuration":86,"studyType":87,"phases":4,"briefSummary":88,"conditions":89,"keywords":101,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":43},"100589453","cardiac-assessment-for-recurrent-stroke-risk-evaluation-in-atrial-fibrillation-100589453","NCT06954610","Cardiac Assessment for Recurrent Stroke Risk Evaluation in Atrial Fibrillation","CARE-AF: Cardiac Assessment for Recurrent Stroke Risk Evaluation in Atrial Fibrillation","CARE-AF","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Written informed consent (by patient, next of kin or legally authorised representative)\n* Permanent, persistent, or paroxysmal AF previously known or diagnosed during the index hospitalisation\n* Acute (≤7 days), symptomatic ischemic stroke\n\nExclusion Criteria:\n\n* Life expectancy \\\u003C1 year according to the opinion of the investigator\n* Patient is unlikely to attend follow-up visits",{"count":85,"type":20},500,"12 Months","OBSERVATIONAL","Background\n\nAtrial fibrillation (AF) is the most common cardiac arrhythmia, affecting up to 10% of the elderly. Ischemic stroke is the main complication of AF and cardioembolism is one of the leading causes of ischemic stroke, accounting for approximately one third of cases. Oral anticoagulant therapy (OAC) is a cornerstone in stroke prevention in patients with AF. According to randomized controlled trials of direct oral anticoagulants, a residual risk of ischemic stroke of 1-2% per year for so-called \"breakthrough stroke\" remains, despite adequate intake of OAC. The majority (\\>70%) of these breakthrough strokes are cardioembolic in nature and only a minority are related to medication issues (e.g. non-compliance) or other, non-AF related etiologies. Stroke recurrence risk after such a breakthrough stroke markedly increases to 8-9% per year indicating a particularly high-risk situation. Why OAC fails in certain patients, but not in others remains as poorly understood, as does the reason why the subsequent risk of stroke is so high.\n\nCurrent risk stratification tools, such as the widely used CHA2DS2-VA(Sc)-score, fail to predict stroke risk in such a high-risk cohort, as they were intended to guide the initiation of OAC in low to moderate risk patients. In light of new therapeutic strategies currently being investigated, such as percutaneous left atrial appendage occlusion in patients with breakthrough strokes (ELAPSE - NCT05976685) or in AF-patients deemed high-risk (LAAOS IV - NCT05963698), improved risk stratification and characterization of high-risk AF patients is highly warranted.\n\nSeveral clinical factors, such as those reflected in the CHA2DS2-VA(Sc)-score, and especially a high AF-burden are associated with increased risk of cardioembolic stroke. Several cardiac serum biomarkers are thought to be surrogates not only of cardiac function, but also of cardioembolic risk. Reflecting ventricular and atrial wall tension, myocardial injury, oxidative stress and thrombogenicity, elevated NT-proBNP, MR-proANP, high-sensitive Troponin T and D-Dimers have all been associated with cardioembolic stroke in different AF and non-AF populations. As the main location of thrombus formation, the left atrium (LA) and more specifically its appendage (LAA) are of particular interest in the pathogenesis of cardioembolism. Pronounced LA-enlargement, compared to a normal-sized LA, correlates with an increased risk of cardioembolism in AF-patients. As over 80% of thrombi form within the LAA, several LAA-characteristics, such as slower LAA-flow velocity and larger LAA-orifice area have also been demonstrated to be associated with higher stroke risk. Although there is data on each one of these factors, they have only been investigated in low to moderate risk populations, such as AF-patients without prior stroke, OAC-naïve patients, or even within the general population as a whole. Their role in high-risk AF-patients and in breakthrough stroke is unknown.\n\nHypothesis\n\nThe investigators hypothesize that specific clinical factors, serum cardiac biomarkers and markers of LA- and LAA-morphology and function are associated with breakthrough stroke \u002F OAC-failure and may improve risk stratification.\n\nMethods\n\nCARE-AF is a single-center, prospective cohort study conducted at the Stroke Center of the Inselspital, University Hospital Bern, Switzerland. Patients with an index ischemic stroke and AF (breakthrough and non-breakthrough cases) will be enrolled. The investigators will collect clinical data, serum cardiac biomarkers and echocardiographic indices of the LA and LAA. All patients will receive standardized annual follow-ups until the end of the study, defined as 12 months after the inclusion of the last participant. The primary endpoint is ischemic stroke or systemic embolism during follow-up. First, in a cross-sectional design, the study will assess the association between serum cardiac biomarkers and echocardiographic indices among patients with breakthrough vs. non-breakthrough stroke as index event, applying multivariate regression models. Second, the investigators will perform a longitudinal analysis assessing the association between the variables mentioned above and breakthrough stroke as index event with the primary endpoint, using multivariate Cox regression models. The study aims to enroll a minimum of 500 patients, which provides sufficient power to detect a clinically meaningful adjusted hazard ratio for recurrent stroke of 1.5 with 80% power at an alpha level of 5%.\n\nConclusion\n\nThe results of this project will enhance understanding of the role of specific clinical factors, cardiac serum biomarkers and echocardiographic indices in the residual risk of stroke in patients with AF on anticoagulation therapy. They may improve current risk stratification and have the potential to help guide therapeutic decisions in high-risk situations considering evolving therapeutic possibilities.",[90,91,92,93,94,62,95,60,96,97,98,99,100,26],"Ischemic Stroke","Atrial Fibrillation","Cerebrovascular Disorders","Brain Diseases","Central Nervous System Diseases","Arrhythmias, Cardiac","Brain Infarction","Brain Ischemia","Infarction Cerebral","Stroke","Cardioembolic Stroke",[102,103,104,105,106,107,108,109],"Ischemic stroke","Direct oral anticoagulation","Anticoagulation","Breakthrough stroke","Risk stratification","Atrial fibrillation","Anticoagulant therapy","Direct oral anticoagulant","2025-11-17",{"date":112,"type":35},"2025-11-20",{"date":114,"type":35},"2025-11-04",{"date":116,"type":20},"2028-06-30",{"name":118,"class":42},"Insel Gruppe AG, University Hospital Bern",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":127,"conditions":128,"keywords":135,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":43},"100468249","patient-similarity-for-decision-making-in-prevention-of-cardiovascular-toxicity-pact-a-feasibility-study-100468249","NCT05377320","PAtient Similarity for Decision-Making in Prevention of Cardiovascular Toxicity (PACT): A Feasibility Study","Inclusion Criteria:\n\n1. Patients ≥18 years with a history of cancer.\n2. Have not previously visited a cardiologist to assess cardiovascular risk after cancer diagnosis.\n3. Clinically at intermediate, high, or very high risk for cardiovascular diseases determined based on imprecise clinical risk models, such as those used for cardiac dysfunction.\n4. Ability to understand a written informed consent form, and willing to sign it prior to study registration.\n\nExclusion Criteria:\n\n1. Patient \\\u003C18 years.\n2. Without a personal history of cancer.\n3. Existing cardiomyopathy diagnosed after cancer diagnosis.\n4. Documented cognitive impairment.\n5. Patient or patient representative who is unable and unwilling to sign the informed consent form.",{"count":126,"type":20},60,"This is a single-center, double-arm, open-label, randomized feasibility study that will determine whether a novel clinical decision aid accessed via the electronic health record will be acceptable to both cancer survivors and their cardiologists, will favorably impact appropriate medication use and cardiac imaging surveillance, and will improve clinician and patient decision-making, perception, and behavior towards cardioprotective medication usage and cardiovascular disease imaging utilization.",[64,129,130,26,131,132,133,134],"Coronary Artery Disease","Peripheral Artery Disease","Hypertension","Diabetes Mellitus","Cardiomyopathies","Cardiotoxicity",[136,137,138,139,140,141,142],"clinical decision aid","cancer","cardiac dysfunction","cardio-oncology","artificial intelligence","machine learning","adverse events","NOT_YET_RECRUITING","2025-10-09",{"date":146,"type":35},"2025-10-14",{"date":148,"type":20},"2026-12",{"date":150,"type":20},"2028-12",{"name":152,"class":42},"Medical College of Wisconsin",{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":75},"100449964","the-orchestrate-myocarditis-registry-100449964","NCT05139329","The ORCHESTRATE-Myocarditis Registry","Observational Registry of Ischemia Negative Chest Pain as the Presentation of Underlying Myocarditis: the ORCHESTRATE-Myocarditis Registry","Inclusion criteria\n\n1. Age \\>18 years\n2. Patients with a presentation of typical or atypical chest pain (ICD-10 Code R07.89, R07. 9)\n3. Patients with a negative ischemic workup: (including Coronary Artery Calcium Scoring\u002FCTA, MPI, Nuclear Stress test, LHC\u002Fangiography showing anything greater than \"non-obstructive CAD\")\n\nExclusion criteria\n\n1. Patients with any evidence of positive ischemic workup as the cause of typical\u002Fatypical chest pain (as seen on Coronary Artery Calcium Scoring\u002FCTA, MPI, Nuclear Stress test, LHC\u002Fangiography)\n2. Previously documented history of Prinzmetal angina or coronary vasospasm\n3. History of prior myocardial infarction\n4. History of any prior CAD with severity greater than \"non-obstructive CAD\" in all 3 coronary arteries\n5. History of LVEF\\\u003C40%\n6. Previously documented history of pericarditis\n7. Previously documented history of costochondritis",{"count":161,"type":20},382,"A retrospective, observational study consisting of patients who presents with typical\u002Fatypical chest pain and have an ensuing negative ischemic evaluation",[164,26,165],"Myocarditis","Chest Pain","2025-08-27",{"date":168,"type":35},"2025-08-28",{"date":170,"type":20},"2026-01",{"date":172,"type":20},"2026-05",{"name":174,"class":42},"Kansas City Heart Rhythm Research Foundation",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":183,"conditions":184,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":43},"100387190","study-of-circulating-monocytes-in-patients-with-ischemic-vascular-disease-100387190","NCT04321512","Study of Circulating Monocytes in Patients With Ischemic Vascular Disease","Inclusion Criteria:\n\n* STEMI Patients: Men and women aged 18 years and over, with symptoms, physical signs and ECG changes characteristic of STEMI.\n* NSTEMI Patients: Men and women aged 18 years and over, with symptoms, physical signs and ECG changes characteristic of NSTEMI.\n* Stable CAD Patients: men and women aged 18 years and older with coronary artery disease proven by prior MI history, angiography or stress test but without any unstable angina or acute coronary syndrome.\n* Ischemic Stroke Patients: Men and women aged 18 years and over, with symptoms, physical signs and CT\u002FMRI changes characteristic of ischemic stroke.\n* Healthy Controls: Men and women aged 18 years and over, without heart failure, coronary disease, hypertension, diabetes or other chronic diseases. Control subjects will be recruited from within the community of UConn Health via advertisement.\n\nExclusion Criteria:\n\n* Subjects who are unable to give informed consent (with the exception of the ischemic stroke arm patients, see Protocol Design below) and pregnant subjects.\n* Subjects who had any history of embolic, ischemic or hemorrhagic stroke within the last 12 months.",{"count":182,"type":20},300,"The purpose of this research study is to discover the functions of circulating white blood cells, called monocytes, and associated circulating substances in heart attack and ischemic stroke patients. Ischemic Strokes (clots) occur as a result of an obstruction within a blood vessel supplying blood to the brain. A type of monocyte carrying a surface marker called \"P2X4\" helps the immune system sense and respond to danger signals from the body such as heart muscle and brain tissue injuries.\n\nThe researchers expect to learn more about how these monocyte cells react to heart and brain tissue injury, and how the cells may then produce proteins or other chemical substances which promote the healing of heart muscle after heart attack and brain tissue after an ischemic stroke.",[58,185,26],"Stroke, Ischemic","2025-08-10",{"date":188,"type":35},"2025-08-14",{"date":190,"type":35},"2013-12-01",{"date":192,"type":20},"2027-12-01",{"name":194,"class":42},"UConn Health",{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":201,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":211,"locationsCount":43},"100114995","circulating-markers-for-ischemic-heart-disease-100114995","NCT00762333","Circulating Markers for Ischemic Heart Disease","Inclusion Criteria:\n\n* men and women, 18 years of age and over with acute myocardial infarction (determined by positive cardiac markers -CKMB\u002F troponin) with or without heart failure (dyspnea, rales, edema, elevated jugular venous pressure, ascites).\n* Heart failure can be diagnosed using imaging evidence such as dilated heart, poor contractile function or echocardiographic Doppler evidence of diastolic dysfunction or elevated right- or left-sided filling pressures\n* A control group of male subjects age 60 and older without history of MI or heart disease\n\nExclusion Criteria:\n\n* Subjects unable to give consent\n* Subjects who have undergone cardiac or non-cardiac surgery in the 3 months prior to enrollment",{"count":202,"type":20},550,"The purpose of this research is to determine if two proteins in the blood are increased during acute myocardial infarction and whether their levels are higher in those who develop heart failure than those who do not. These two proteins are produced and potentially released when the heart muscle is damaged. They may then be released into the blood and be detected by standard method in the research laboratory. At this time, detection of an increase in these proteins in the blood is not known to be associated with any disease or myocardial infarction.",[58,26,205],"Congestive Heart Failure",{"date":207,"type":35},"2025-08-12",{"date":209,"type":4},"2007-06",{"date":71,"type":20},{"name":194,"class":42},{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":218,"eligibilityCriteria":219,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":220,"targetDuration":4,"studyType":21,"phases":222,"briefSummary":224,"conditions":225,"keywords":229,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":4},"100550486","phase-3-interleukin-6-receptor-inhibition-for-symptomatic-intracranial-atherosclerosis-100550486","NCT06447701","Interleukin-6 Receptor Inhibition for Symptomatic Intracranial Atherosclerosis","Effect of Interleukin-6 Receptor Inhibition for Avoiding Recurrence of Ischemic Stroke in Patients With Symptomatic Intracranial Atherosclerosis: a Double-blind, Randomized, Placebo-controlled Trial","IRIS-sICAS","Inclusion Criteria:\n\n* Male or non-pregnant women with acute stroke symptoms aged over 18 years.\n* Patients having an ischemic stroke or a TIA prior to randomization (Patients having an acute ischemic stroke within 72 hours with NIHSS score≤5 at baseline, or patients having a TIA within 72 hours with Oxfordshire Community Stroke Project on the basis of age, blood pressure, clinical features, and duration of TIA symptoms (ABCD2) score≥4 at baseline).\n* The entry event is attributed to symptomatic atherosclerosis (50-99%) in an intracranial qualifying artery (intracranial carotid artery (C4-7), middle cerebral artery (M1), intracranial vertebral artery or basilar artery) confirmed by CT, MR angiography, or digital subtraction angiography.\n* Informed consent obtained from patients or their legal representatives.\n* Willing to be followed up as required by the clinical study protocol.\n\nExclusion Criteria:\n\n* Thrombolytic therapy or thrombectomy within 24 hours prior to enrollment.\n* Pre-stroke mRS score ≥ 2.\n* Combined or previous intracranial hemorrhage: hemorrhagic stroke, epidural hematoma, subdural hematoma, intraventricular hemorrhage, subarachnoid hemorrhage, etc.\n* Any of the following unequivocal cardiac source of embolism: chronic or paroxysmal atrial fibrillation, sinus node dysfunction, mitral stenosis, prosthetic heart valves, endocarditis, left ventricular mural thrombus or valvular vegetation, myocardial infarction within three months, dilated cardiomyopathy, spontaneous echogenic defects in the left atrium or an ejection fraction of less than 30%.\n* Intracranial arterial stenosis due to arterial dissection, Moya Moya disease; herpes zoster, varicella zoster or other viral vasculopathy; neurosyphilis; radiation induced vasculopathy; fibromuscular dysplasia; sickle cell disease; neurofibromatosis; post-partum angiopathy; suspected vasospastic process, suspected recanalized embolus; any known vasculitic disease.\n* Extracranial stenosis ≥50%, subclavian arterial stenosis≥50% or subclavian steal syndrome.\n* Previous interventions for intracranial arterial stenosis.\n* Concurrent intracranial tumors, intracranial aneurysms or arteriovenous malformations\n* Neutrophil \\\u003C 2×10 9\u002FL.\n* Platelet \\\u003C 100×10 9\u002FL.\n* Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels greater than 1.5 times the upper limit of normal.\n* Active infections including localized.\n* Evidence of HIV or hepatitis B positivity.\n* Positive tuberculosis-related tests.\n* Concurrent peptic ulcer, diverticulitis or inflammatory bowel disease.\n* Concurrent malignant tumors, recent bone marrow transplant or recent organ transplant.\n* Systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg despite blood pressure control.\n* Known allergy to tocilizumab or excipients.\n* Use of immunosuppressive drugs or systemic use of antibiotics.\n* Received any live or live attenuated vaccine within 4 weeks prior to enrollment or plan to receive a live or live attenuated vaccine during the study.\n* History of demyelination or presence of neurological symptoms suggestive of demyelination.\n* Previously existing neurological or psychiatric disorders that could potentially confuse neurological function assessment.\n* An expected survival less than 90 days.\n* Participation in another interventional clinical study.\n* Patients unsuitable for enrollment in the clinical trial according to investigators decision making.",{"count":221,"type":20},486,[223],"PHASE3","IRIS-sICAS is a multicenter, randomized, double-blind, placebo-controlled clinical trialis a multicenter, randomized, double-blind, placebo-controlled clinical trial, to assess the safety and efficacy of tocilizumab injection in lowering the incidence of newly diagnosis ischemic stroke and improving prognosis in symptomatic intracranial atherosclerosis patients.",[93,90,26,99,226,227,228],"Cerebral Infarction","Atherosclerosis of Artery","Atheroscleroses, Intracranial",[230,231,232,102],"Tocilizumab","Symptomatic intracranial atherosclerotic stenosis","Recurrence","2025-07-24",{"date":235,"type":35},"2025-07-28",{"date":237,"type":20},"2025-10-30",{"date":239,"type":20},"2029-06-30",{"name":241,"class":42},"Zhujiang Hospital",{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":248,"eligibilityCriteria":249,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":250,"targetDuration":252,"studyType":87,"phases":4,"briefSummary":253,"conditions":254,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":259,"leadSponsor":261,"locationsCount":43},"100119623","evaluation-of-patients-with-non-obstructive-coronary-arteries-100119623","NCT00823563","Evaluation of Patients With Non-obstructive Coronary Arteries","Evaluation of Patients With Angina in the Absence of Obstructive Coronary Artery Disease","noCAD","Inclusion Criteria:\n\n1. Patient referred for elective coronary angiography because of a reasonable clinical suspicion of coronary ischemia.\n2. Presence of angina or an anginal equivalent (including chest, back, shoulder, arm, neck, jaw discomfort, or shortness of breath brought on by physical exertion, emotional stress, or certain times of day\u002Fmonth).\n\nExclusion Criteria:\n\n1. Asymptomatic (such as a pre-op cath)\n2. Status-post heart transplant\n3. Age \\\u003C18\n4. Renal insufficiency (creatinine \\>1.5)\n5. Presence of an acute coronary syndrome (STEMI or NSTEMI), Tako-tsubo, an abnormal ejection fraction (EF\\\u003C55%), cardiogenic shock, or recent VT\u002FVF\n6. Presence of another likely explanation of chest pain, such as pulmonary hypertension or aortic stenosis\n7. History of adverse reaction to any of the medications being used (acetylcholine, nitroglycerin, adenosine, or heparin)\n8. Currently taking vasoactive medication (such as nitroglycerin)\n9. Inability to provide an informed consent, including an inability to speak, read, or understand English, Spanish, Chinese, Farsi, Japanese, Korean, Russian, or Vietnamese\n10. A hearing impairment that won't allow for a typical verbal conversation or a visual impairment that won't allow for reading of the written consent\n11. Participation in another study (with the exception of the Stanford Gene-PAD study)\n12. A potentially vulnerable subject (including minors, pregnant women, economically and educationally disadvantaged, decisionally impaired, and homeless people)",{"count":251,"type":20},2000,"15 Years","Patients with angina and non-obstructive CAD are common within clinical practice, but remain a challenge with regard to diagnosis and treatment. When these patients undergo a comprehensive evaluation at the time of invasive coronary angiography, occult coronary abnormalities are frequently found. We hope to learn the overall prevalence and presentation of these occult coronary abnormalities and its long term outcome in this patient population.",[165,26],"2025-06-02",{"date":257,"type":35},"2025-06-05",{"date":209,"type":35},{"date":260,"type":20},"2047-06",{"name":262,"class":42},"Stanford University",{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":4,"eligibilityCriteria":269,"healthyVolunteers":11,"sex":16,"minAge":270,"maxAge":271,"enrollmentInfo":272,"targetDuration":4,"studyType":21,"phases":274,"briefSummary":275,"conditions":276,"keywords":4,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":4},"100504260","la-improves-the-prognosis-of-patients-with-icvd-100504260","NCT05845983","LA Improves the Prognosis of Patients With ICVD","Lactobacillus Acidophilus Improves the Prognosis (Cognitive Function) of Patients With Ischemic Cerebrovascular Disease After Surgery: a Multicenter, Prospective, Three-blind, Placebo-randomized Controlled Study","Inclusion Criteria:\n\n1. Between 35 and 65 years old;\n2. Han nationality;\n3. Diagnosed as ischemic cerebrovascular disease with mild to moderate symptoms;\n4. Can communicate normally, complete neuropsychological tests independently, and sign informed consent;\n5. No previous surgical history;\n6. No contraindications such as PET, MRI and DSA;\n7. No history of stroke identified by imaging;\n8. No family history of other chronic diseases, cancer, mental illness or dementia;\n9. Improved Rankin scale score ≤2;\n10. Ischemic symptoms appeared in the carotid area ≤3 months before the visit;\n11. In line with the surgical treatment of ischemic cerebrovascular disease;\n\nExclusion Criteria:\n\n1. previous dementia;\n2. hearing or visual impairment;\n3. Drugs that may or are known to influence cognitive abuse;\n4. alcohol addiction;\n5. Diagnosis of depression, schizophrenia and other psychiatric diseases;\n6. MRI showed severe cerebral infarction;\n7. Those allergic to Lactobacillus acidophilus;\n8. Baseline CT showed intracranial hemorrhage;\n9. ischemic onset accompanied by epilepsy;\n10. illiteracy;\n11. pregnancy or breastfeeding;\n12. any serious medical condition that may interact with treatment;","35 Years","65 Years",{"count":273,"type":20},236,[23],"Ischemic cerebrovascular disease will cause serious harm to the life and safety of patients, and the treatment prognosis is poor. Numerous clinical trials have demonstrated that probiotics can improve cognitive function in people under multimodal. We have previously found that Lactobacillus acidophilus administration could improve cognitive impairment in MCAO and BCAS mice. Therefore, Based on the above research background and the basis of previous studies, we believe that the administration of Lactobacillus acidophilus solid drink (pure Lactobacillus acidophilus strain) can improve the cognitive function of patients with cerebral ischemia through the \"brain-gut axis\".",[26,277,278],"Cerebrovascular Ischemia","Cognitive Impairment","2023-04-26",{"date":281,"type":35},"2023-05-06",{"date":283,"type":20},"2023-05-04",{"date":285,"type":20},"2028-12-31",{"name":287,"class":42},"Huaqiu Zhang"]